MedTrace Logo

Zoledronate With Atorvastatin in Renal Cell Carcinoma

NCT00490698 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2013-03-18

Study results available
· View outcomes & findings →

Summary

Objectives:

Primary:

Evaluate clinical outcome based on the time to skeletal events after bone-targeted therapy

Secondary:

1. Evaluate clinical outcome based on the presence of calcification at the site of osteolytic metastases
2. Measure bone-formation and resorption markers at baseline and during bone-targeted therapy.
3. Assess effect of the bone-targeted regimen on serum cholesterol levels

Conditions

Interventions

DRUG

Zoledronate

4 mg IV Once Every 4 Weeks

DRUG

Atorvastatin

20 mg PO Daily

Sponsors & Collaborators

Principal Investigators

  • Shi-Ming Tu, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00490698 on ClinicalTrials.gov